For the interim period of the fiscal year ending March 2027, consolidated net sales were 5,210,721 thousand yen, down 6.1% year-over-year. Operating income was 28,514 thousand yen, ordinary income was 26,771 thousand yen, and interim net income attributable to owners of parent was 5,221 thousand yen, representing a steep decline. Net assets at the interim period-end were 9,390,178 thousand yen and the equity ratio was 79.9%. Full-year forecasts for 2027 remain unchanged. Management continues initiatives to strengthen the operating base, including logistics integration and introduction of approx. new brands.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4925","jir_company_name":"HABA Laboratories,Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4925-20261113-01.pdf","jir_short_summary":"For the interim period of the fiscal year ending March 2027, consolidated net sales were 5,210,721 thousand yen, down 6.1% year-over-year. Operating income was 28,514 thousand yen, ordinary income was 26,771 thousand yen, and interim net income attributable to owners of parent was 5,221 thousand yen, representing a steep decline. Net assets at the interim period-end were 9,390,178 thousand yen and the equity ratio was 79.9%. Full-year forecasts for 2027 remain unchanged. Management continues initiatives to strengthen the operating base, including logistics integration and introduction of approx. new brands.","jir_summary":"### Overview of Results\nThis report discloses consolidated results for the interim period of the fiscal year ending March 2027. Net sales amounted to 5,210,721 thousand yen, a 6.1% decrease from the same period last year. The core mail-order business faced challenges acquiring new customers, and store sales declined due to natural disasters and reduced tourism. Both the cosmetics and health food categories fell short of the prior year, resulting in substantial decreases in operating income, ordinary income and interim net income. The company will continue cost reduction and profit-structure reforms, reorganization of skin-concern-specific product lines, and strengthening of digital initiatives.\n\n### Outlook and Financial Position\nThe company will promote personnel capital strengthening, logistics integration, review of unprofitable stores, and SKU optimization under the Phase II medium-term plan. The full-year forecast for fiscal 2027 remains unchanged from the time of publication. Cash and cash equivalents stood at 4,770,477 thousand yen, net assets were 9,390,178 thousand yen, and the equity ratio improved from 76.2% to 79.9%. Dividend forecasts remain unchanged.","jir_financial_highlights":"Net Sales: 5,210,721 thousand yen (Down 6.1% Year-over-Year)\nOperating Income: 28,514 thousand yen (Down 88.9% Year-over-Year)\nOrdinary Income: 26,771 thousand yen (Down 89.4% Year-over-Year)\nInterim Net Income Attributable to Owners of Parent: 5,221 thousand yen (Down 97.2% Year-over-Year)\nTotal Assets: 11,758,148 thousand yen\nEquity Ratio: 79.9%","jir_category":"","jir_hashtags":"#HABALaboratories, #Earnings","jir_key_figures":"Net Sales: 5,210,721 thousand yen (YoY -6.1%)\nOperating Income: 28,514 thousand yen (YoY -88.9%)\nInterim Net Income Attributable to Owners of Parent: 5,221 thousand yen (YoY -97.2%)","jir_meta_title":"HABA Laboratories,Inc. \u2014 Interim Financial Summary for FY March 2027\uff5cNet Sales Decline Year-over-Year","jir_meta_description":"Interim financial summary of HABA Laboratories,Inc. for the fiscal year ending March 2027. Net sales 5,210 million yen, operating income 28 million yen, net income 5,221 thousand yen. Analysis of business impacts and strategies such as logistics integration and SKU optimization, and unchanged full-year outlook.","jir_og_title":"HABA Laboratories,Inc. \u2014 Key Points from the Interim Financial Results","jir_og_description":"HABA Laboratories,Inc.'s interim results show a decline in sales while maintaining financial soundness. The company will continue logistics integration and new brand strategies, with the full-year outlook unchanged.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59553,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-153100","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n